The new INTERACT meeting process can be a critical step for start-up sponsors to avoid early stumbles in their attempts to move into human trials, US Food and Drug Administration officials emphasized during a recent webinar offering “Regulatory Do’s and Don’ts” for small businesses.
Key Takeaways
-
FDA officials want start-up sponsors to take advantage of opportunities to meet with the agency.
-
The agency said INTERACT meetings are not...
“I highly recommend you take advantage of the meeting opportunities” outlined during the webinar, Center for Biologics Evaluation and Research CMC Reviewer Karin Knudson said. “In particular for early-phase studies,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?